The enrollment expansion and delayed readout push the binary catalyst to mid-2027, extending the timeline but potentially increasing the trial's statistical power. The blinded observation of fewer recurrences is directionally positive but unconfirmed. Monitor for any interim data releases or financing updates given the extended cash burn period.
Price Chart
Executive Summary
Cardiol Therapeutics announced it achieved the original 110-patient enrollment target for its Phase III MAVERIC trial ahead of schedule and plans to expand enrollment to up to 150 patients following a blinded review showing fewer-than-expected recurrences. Topline results are now expected in mid-2027 (previously Q1 2027), and the company has cash runway into Q1 2028 to fund completion. The expansion is intended to preserve statistical power for a robust efficacy assessment of CardiolRx in recurrent pericarditis.
Key Facts
- Phase III MAVERIC trial achieved original 110-patient enrollment target ahead of end-of-September 2026 guidance.
- Steering Committee recommends expanding enrollment to up to 150 patients to capture sufficient events for robust efficacy assessment.
- Blinded review showed fewer-than-expected pericarditis recurrences, which the company views as encouraging.
- Topline results now anticipated in mid-2027, delayed from previous Q1 2027 guidance.
- Existing capital expected to fund MAVERIC completion with cash runway into Q1 2028.
- CardiolRx has FDA Orphan Drug Designation for pericarditis, including recurrent pericarditis.
Financial Impact
No financial figures provided; cash runway extends into Q1 2028, sufficient to complete the trial.
Risk Factors
- Topline results delayed to mid-2027, extending uncertainty and cash burn period.
- Expanded enrollment increases trial costs; cash runway into Q1 2028 may be tight if additional delays occur.
- Blinded observation of fewer recurrences could reflect either drug efficacy or lower-than-expected event rate in both arms, which may reduce statistical power despite expansion.
- No revenue or approved product; stock is binary on Phase III success.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001279569-26-000905 |
| Document: cardiol6k.htm | 0001279569-26-000905 |
| Document: 0001279569-26-000905-index-headers.html | 0001279569-26-000905 |
| Document: 0001279569-26-000905-index.html | 0001279569-26-000905 |
| Document: 0001279569-26-000905.txt | 0001279569-26-000905 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 23, 2026 4w ago | SC 13G/A | $1.77 | awaiting T+60 | — | $1.15 (−35.03%) |
Sep 23, 2026 4w ago | 6-K | $1.77 | awaiting T+60 | — | $1.15 (−35.03%) |
Sep 16, 2026 5w ago | 6-K | $1.90 | awaiting T+60 | — | $1.15 (−39.47%) |
Sep 10, 2026 6w ago | 6-K | $2.00 | awaiting T+60 | — | $1.15 (−42.36%) |
Sep 10, 2026 6w ago | 6-K | $2.00 | awaiting T+60 | — | $1.15 (−42.36%) |
Sep 9, 2026 6w ago | 6-K | $2.29 | awaiting T+60 | — | $1.15 (−49.67%) |
Aug 5, 2026 11w ago | 6-K | $1.34 | awaiting T+60 | — | $1.15 (−14.18%) |
Jul 14, 2026 15w ago | 6-K | $1.15 $1.32 | ▲ +14.78% | ▲ +11.41% | $1.15 (−0.00%) |
Jul 9, 2026 15w ago | 6-K | $0.9920 $1.41 | ▲ +42.14% | ▲ +40.50% | $1.15 (+15.93%) |
May 26, 2026 22w ago | 6-K | $1.30 $1.96 | ▲ +50.77% | ▲ +48.04% | $1.15 (−11.54%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers